What a proteomic aging clock can tell us
A 204-protein clock, developed using 45,441 UK Biobank participants, was associated with future disease and mortality risk and evaluated in Chinese and Finnish cohorts.
We have never moved faster.
Let’s get better at knowing where to go.
Ideas, evidence and connections for a more human-relevant future in life sciences.
The next leap in life sciences should not be measured only in how much we do. It should be measured in how much earlier we know what to do next.
Connect human-relevant models, meaningful measurements and AI to a decision. Then test it. Learn from it. Change course.
Read the manifestoA conceptual navigation object. Not a biological model or a prediction of success.
What evidence would help us make a better decision, earlier?

Ask human biology earlier.

Measure what matters.

Understand the trajectory.

Build evidence behind the claim.
A 204-protein clock, developed using 45,441 UK Biobank participants, was associated with future disease and mortality risk and evaluated in Chinese and Finnish cohorts.
FDA’s March 2026 draft guidance sets out general scientific considerations for validating New Approach Methodologies in drug development and regulatory submissions.
OECD Test Guideline 439 describes reconstructed human epidermis methods for identifying skin irritation hazards in a defined testing context.
Every note separates the finding, the interpretation and what remains unknown.

Happening today.
See organizer for times · Continuing today
Multiple Boston and Cambridge venues; see individual program pages · Boston
Price not listed · Check individual organizers
No Kendall event indexed today. Here’s what’s on nearby.
Boston BioLife / Healthspan Action Coalition
Save your plans. Registration stays with the organizer.
Source-linked listings, not exhaustive daily coverage. Check organizer pages for time, access and availability.FDA’s M15 resource center brings together templates and examples for assessing model-informed evidence.
FDA issued its final ICH M15 guidance in June 2026.
FDA’s draft NAM guidance outlines general considerations for validation and reporting.
Earlier that an idea is promising.
Earlier that it’s time to change direction.